Foghorn Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 6, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 6, 2025
FHTX$1.90-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(86,620) | $(98,426) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Stock-based compensation expense | 11,893 | 16,186 |
| Depreciation and amortization expense | 3,120 | 3,451 |
| Loss on disposal of property and equipment | — | 3 |
| Impairment of long-lived assets | 2,398 | — |
| Noncash lease expense | 5,682 | 5,210 |
| Accretion of discount on marketable securities | (4,613) | (2,651) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,317 | 741 |
| Accounts payable | (2,475) | 846 |
| Accrued expenses and other liabilities | (564) | (1,797) |
| Operating lease liabilities | (7,942) | (7,514) |
| Deferred revenue | (22,602) | (34,155) |
| Net cash used in operating activities | (100,406) | (118,106) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (906) | (1,224) |
| Purchases of marketable securities | (261,470) | (73,901) |
| Proceeds from maturities of marketable securities | 232,472 | 219,575 |
| Net cash provided by (used in) investing activities | (29,904) | 144,450 |
| Cash flows from financing activities: | ||
| Proceeds from offerings of common stock and pre-funded warrants, net of underwriting discounts and commissions | 103,401 | — |
| Payments of public offering costs | (585) | — |
| Proceeds from issuance of common stock upon exercise of stock options | 2,612 | 1,778 |
| Net cash provided by financing activities | 105,428 | 1,778 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (24,882) | 28,122 |
| Cash, cash equivalents and restricted cash at beginning of period | 82,044 | 53,922 |
| Cash, cash equivalents and restricted cash at end of period | $57,162 | $82,044 |
| Supplemental cash flow information: | ||
| Cash paid for taxes | $860 | $3,551 |
| Supplemental disclosure of noncash investing and financing information: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses | $22 | $35 |
| Reconciliation of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $55,454 | $80,336 |
| Restricted cash (non-current) | 1,708 | 1,708 |
| Total cash, cash equivalents and restricted cash shown in the statement of cash flows | $57,162 | $82,044 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.